Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Osamu Kurai
Randomized Trial of Combined Triple Therapy Comprising Two Types of Peginterferon With Simeprevir in Patients With Hepatitis C Virus Genotype 1b
Hepatology Research
Hepatology
Infectious Diseases
A Study of Hepatocellular Carcinoma Patients Surviving for 10 Years-Comparison of Hepatectomy and Percutaneous Ablation Therapy-
Journal of Microwave Surgery
Related publications
Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response
Hepatology
Medicine
Hepatology
Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients With Genotype 1 Hepatitis C Virus Using Super-Early Viral Response Within 2 Weeks
Journal of Liver
An Integrated Analysis of Elbasvir/Grazoprevir in Korean Patients With Hepatitis C Virus Genotype 1b Infection
Clinical and molecular hepatology
Medicine
Hepatology
Molecular Biology
Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection
Eastern Mediterranean Health Journal
Medicine
Prediction of Treatment Efficacy and Telaprevir-Resistant Variants After Triple Therapy in Patients Infected With Hepatitis C Virus Genotype 1
Journal of Clinical Microbiology
Microbiology
Effectiveness of Elbasvir/Grazoprevir in US Veterans With Chronic Hepatitis C Virus Genotype 1b Infection
Infectious Diseases and Therapy
Infectious Diseases
Microbiology
A Randomized Trial of 24 Versus 48 Weeks of Peginterferon Α-2a in Patients Infected With Chronic Hepatitis C Virus Genotype 2 or Low Viral Load Genotype 1: A Multicenter National Study in Japan
Hepatology International
Hepatology
Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3
SpringerPlus
Multidisciplinary
